Frédéric Knoflach

5.0k total citations · 1 hit paper
59 papers, 3.9k citations indexed

About

Frédéric Knoflach is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Frédéric Knoflach has authored 59 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Cellular and Molecular Neuroscience, 38 papers in Molecular Biology and 8 papers in Cognitive Neuroscience. Recurrent topics in Frédéric Knoflach's work include Neuroscience and Neuropharmacology Research (45 papers), Receptor Mechanisms and Signaling (21 papers) and Nicotinic Acetylcholine Receptors Study (15 papers). Frédéric Knoflach is often cited by papers focused on Neuroscience and Neuropharmacology Research (45 papers), Receptor Mechanisms and Signaling (21 papers) and Nicotinic Acetylcholine Receptors Study (15 papers). Frédéric Knoflach collaborates with scholars based in Switzerland, United States and United Kingdom. Frédéric Knoflach's co-authors include Uwe Rudolph, John A. Kemp, Pari Malherbe, Vincent Mutel, Maria‐Clemencia Hernandez, Jürgen Wichmann, Joseph G. Wettstein, Dietmar Benke, H. Möhler and Edilio Borroni and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Frédéric Knoflach

58 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes

2011 554 citations Frédéric Knoflach et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédéric Knoflach Switzerland	30	2.5k	1.9k	697	584	330	59	3.9k
Mark A. Varney United States	34	3.5k 1.4×	2.3k 1.2×	737 1.1×	614 1.1×	230 0.7×	85	4.6k
James N.C. Kew United Kingdom	39	3.5k 1.4×	3.0k 1.5×	712 1.0×	560 1.0×	301 0.9×	71	4.8k
Lori L. McMahon United States	34	1.8k 0.7×	1.5k 0.8×	674 1.0×	481 0.8×	311 0.9×	80	3.4k
Xavier Langlois Belgium	38	2.3k 0.9×	2.1k 1.1×	397 0.6×	510 0.9×	330 1.0×	104	4.2k
Guido Maura Italy	39	2.6k 1.0×	2.1k 1.1×	504 0.7×	420 0.7×	290 0.9×	128	4.0k
Vincent Mutel Switzerland	38	3.3k 1.3×	2.8k 1.4×	612 0.9×	366 0.6×	345 1.0×	85	4.6k
Edilio Borroni Switzerland	35	1.9k 0.8×	1.5k 0.8×	806 1.2×	843 1.4×	250 0.8×	91	4.3k
Gisela Grecksch Germany	35	2.3k 0.9×	1.2k 0.6×	736 1.1×	458 0.8×	214 0.6×	94	3.6k
Henry Sershen United States	43	3.4k 1.4×	2.9k 1.5×	589 0.8×	672 1.2×	347 1.1×	164	5.4k
Yossef Itzhak United States	43	3.6k 1.4×	2.8k 1.4×	584 0.8×	552 0.9×	302 0.9×	119	5.1k

Countries citing papers authored by Frédéric Knoflach

Since Specialization

Citations

This map shows the geographic impact of Frédéric Knoflach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Knoflach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Knoflach more than expected).

Fields of papers citing papers by Frédéric Knoflach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Knoflach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Knoflach. The network helps show where Frédéric Knoflach may publish in the future.

Co-authorship network of co-authors of Frédéric Knoflach

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Knoflach. A scholar is included among the top collaborators of Frédéric Knoflach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Knoflach. Frédéric Knoflach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Janz, Philipp, Frédéric Knoflach, Konrad Bleicher, et al.. (2023). Selective oxytocin receptor activation prevents prefrontal circuit dysfunction and social behavioral alterations in response to chronic prefrontal cortex activation in male rats. Frontiers in Cellular Neuroscience. 17. 1 indexed citations

Kasaragod, Vikram Babu, Tomas Malinauskas, Judith A. Lengyel, et al.. (2023). The molecular basis of drug selectivity for α5 subunit-containing GABAA receptors. Nature Structural & Molecular Biology. 30(12). 1936–1946. 6 indexed citations

Knoflach, Frédéric & Daniel Bertrand. (2021). Pharmacological modulation of GABAA receptors. Current Opinion in Pharmacology. 59. 3–10. 20 indexed citations

Knoflach, Frédéric, et al.. (2018). Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission. Journal of Visualized Experiments. 2 indexed citations

Knoflach, Frédéric, Maria‐Clemencia Hernandez, & Daniel Bertrand. (2018). Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission. Journal of Visualized Experiments. 5 indexed citations

Hierlemann, Andreas, et al.. (2018). Parvalbumin expression and gamma oscillation occurrence increase over time in a neurodevelopmental model of NMDA receptor dysfunction. PeerJ. 6. e5543–e5543.

Bolognani, Federico, Lisa Squassante, Xavier Liogier D’ardhuy, et al.. (2015). RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273). Neurology. 84(14_supplement). 5 indexed citations

Malherbe, Pari, Frédéric Knoflach, Anne Marcuz, et al.. (2014). Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization. Neuropharmacology. 86. 259–272. 4 indexed citations

Sahdeo, Sunil, Tanya L. Wallace, Ryoko Hirakawa, et al.. (2014). Characterization of RO5126946, a Novel α7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator. Journal of Pharmacology and Experimental Therapeutics. 350(2). 455–468. 20 indexed citations

10.

Martínez‐Cué, Carmen, Paula Martínez, Noemı́ Rueda, et al.. (2013). Reducing GABA _A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome. Journal of Neuroscience. 33(9). 3953–3966. 122 indexed citations

11.

Goeldner, Celia, Theresa M. Ballard, Frédéric Knoflach, et al.. (2012). Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 64. 337–346. 75 indexed citations

12.

Buettelmann, Bernd, Theresa M. Ballard, Rodolfo Gasser, et al.. (2009). Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA α5 inverse agonists with potential for the treatment of cognitive dysfunction. Bioorganic & Medicinal Chemistry Letters. 19(20). 5958–5961. 14 indexed citations

13.

Woltering, Thomas J., Geo Adam, Alexander Alanine, et al.. (2007). Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1. Bioorganic & Medicinal Chemistry Letters. 17(24). 6811–6815. 21 indexed citations

14.

Vieira, Eric, Jörg Huwyler, Synèse Jolidon, et al.. (2005). 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorganic & Medicinal Chemistry Letters. 15(20). 4628–4631. 82 indexed citations

15.

Malherbe, Pari, Frédéric Knoflach, Clemens Broger, et al.. (2001). Identification of Essential Residues Involved in the Glutamate Binding Pocket of the Group II Metabotropic Glutamate Receptor. Molecular Pharmacology. 60(5). 944–954. 4 indexed citations

16.

Knoflach, Frédéric, Thomas J. Woltering, Geo Adam, Vincent Mutel, & John A. Kemp. (2001). Pharmacological properties of native metabotropic glutamate receptors in freshly dissociated Golgi cells of the rat cerebellum. Neuropharmacology. 40(2). 163–169. 14 indexed citations

17.

Schaffhauser, Hervé, Frédéric Knoflach, Zaiga Bleuel, et al.. (1998). Multiple pathways for regulation of the KCl-induced [3H]-GABA release by metabotropic glutamate receptors, in primary rat cortical cultures. Brain Research. 782(1-2). 91–104. 35 indexed citations

18.

Cartmell, Jayne, Frédéric Knoflach, J. R. L. Pink, et al.. (1998). Effect of metabotropic glutamate receptor activation on receptor-mediated cyclic AMP responses in primary cultures of rat striatal neurones. Brain Research. 791(1-2). 191–199. 14 indexed citations

19.

Möhler, H., Frédéric Knoflach, Jacques Paysan, et al.. (1995). Heterogeneity of GABAA-receptors: cell-specific expression, pharmacology, and regulation. Neurochemical Research. 20(5). 631–636. 68 indexed citations

20.

Knoflach, Frédéric, Marika Villa, Stephan Kellenberger, et al.. (1991). The γ3‐subunit of the GABA_A‐receptor confers sensitivity to benzodiazepine receptor ligands. FEBS Letters. 293(1-2). 191–194. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact